Marché mondial de la prégabaline – Tendances et prévisions de l’industrie jusqu’en 2031

Analyse et taille du marché de la prégabaline

La prégabaline est un médicament anticonvulsivant qui peut être utilisé pour traiter l'épilepsie, la douleur neuropathique , la fibromyalgie et  le trouble d'anxiété généralisée . Il agit en réduisant les signaux de douleur délivrés par les nerfs blessés dans tout le corps. Selon l'étude de l'année mondiale contre la douleur neuropathique 2014-2015 de l'Association internationale pour l'étude de la douleur, environ 7 à 8 % des adultes souffrent de douleurs chroniques à caractéristiques neuropathiques.

Data Bridge Market Research analyse que le marché mondial de la prégabaline, qui était de 824,75 millions USD en 2023, devrait atteindre 1 088,56 millions USD d'ici 2031 et devrait connaître un TCAC de 3,53 % au cours de la période de prévision. La forme posologique orale domine le segment du marché en raison de la demande croissante de la forme posologique orale de prégabaline. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché de la prégabaline

Market Definition

Pregabalin is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome, and generalized anxiety disorder. It's an epilepsy medication that's used to treat partial seizures. It functions by lowering nerve activity and lowering pain. Anti-epileptic medicines (AEDs) such as Lyrica (pregabalin) and Topamax (topiramate) are used to prevent epileptic seizures. Lyrica is also indicated to treat diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia neuropathic pain.

Pregabalin Market Dynamics

Drivers

• Rise in the Prevalence of Epilepsy

The surging prevalence of epilepsy is a major factor driving the pregabalin market's growth rate during the forecast period. According to the World Health Organization (WHO), an estimated 50 million people are living with epilepsy globally in 2019, with up to 75 percent of them living in resource-poor countries with little or no access to treatment or medical services. Furthermore, approximately 80% of people with epilepsy live in low- and middle-income nations. In the treatment of epilepsy, pregabalin stops seizures by reducing aberrant electrical activity in the brain.

• Extensive application of Lyrica

The growing application of Lyrica is anticipated to propel the market's growth rate. Lyrica (pregabalin) is a fibromyalgia drug approved by the US Food and Drug Administration. Fibromyalgia is a chronic illness that causes long-term, widespread muscle pain and soreness and sleeping difficulties and exhaustion. Lyrica is a drug used to treat nerve signals. Fibromyalgia affects over 4 million individuals in the United States, or about 2% of the adult population, according to the Centers for Disease Control and Prevention (CDC). The etiology of fibromyalgia is unknown, but it can be effectively treated and managed. Lyrica has long been used to treat nerve pain in shingles or diabetic neuropathy patients. The drug Lyrica is also used to treat partial seizures.

• Rising geriatric population

Neuropathic pain and certain anxiety disorders are more prevalent in the elderly population. With a growing global aging demographic, there is an increased demand for medications that address age-related health issues. Pregabalin's effectiveness in managing pain and anxiety makes it a valuable option for this demographic, thereby driving market growth.

• Growing investment in healthcare facilities

Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. The rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Research and development for new indications

Investing in research and development to explore new therapeutic indications for pregabalin could open up new markets and revenue streams. Identifying and validating additional medical conditions where pregabalin demonstrates efficacy could lead to expanded usage and increased market share.

• Strategic collaborations and partnerships

Collaboration between pharmaceutical companies, research institutions, and healthcare providers can create synergies and drive market growth. Partnerships for clinical trials, marketing initiatives, or distribution agreements can enhance the visibility and accessibility of pregabalin, particularly in regions with unmet medical needs.

Restraints

• Generic competition and patent expiry

The expiration of patents for branded pregabalin products can lead to increased competition from generic manufacturers. Generic alternatives are typically more affordable, which can negatively impact the market share and revenue of the original drug.

• Side effects and safety concerns

Pregabalin, like any medication, may have side effects, and concerns about its safety profile could pose a restraint. As more information becomes available about potential side effects or adverse reactions, healthcare providers and patients may become more cautious in prescribing and using pregabalin.

Challenges

• Intense competition and market saturation

The pregablin market has become highly competitive with the presence of established companies and new entrants. The saturation of the market could pose challenges for companies in terms of differentiation, pricing, and market share.

• Cost containment pressures

Healthcare systems worldwide are under pressure to contain costs, and this can affect the pricing and reimbursement of pharmaceuticals, including pregabalin. Payers may push for lower prices, impacting the revenue potential for manufacturers. Navigating pricing negotiations and demonstrating the value proposition of pregabalin in terms of efficacy and patient outcomes can be challenging.

This pregabalin market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pregabalin market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In June 2023, Food and Drug Administration (FDA) approved SinoT’s ANDA application for PREGABALIN EXTENDED-RELEASE TABLETS 82.5 mg, 165 mg, and 330 mg for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN), and Postherpetic neuralgia (PHN)
• In April 2023, Pakistani pharmaceutical firm AGP Limited acquired a selected portfolio of products from American firm Viatris Inc. The portfolio includes many anti-depressants, including pregabalin, anti-hypertensive, and ophthalmology products

Global Pregabalin Market Scope

The pregabalin market is segmented on the basis of drug class, application, dosage forms, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Application

• Epilepsy
• Neuropathic Pain
• Anxiety Disorder
• Others

Drug Class

• Fibromyalgia Agents
• Anticonvulsants
• Others

Dosage Forms

• Oral Capsule
• 100 mg
• 150 mg
• 200 mg
• 225 mg
• 25 mg
• 300 mg
• 50 mg
• 75 mg
• Oral Solution
• 20 mg/mL
• Oral Tablet, extended release
• 165 mg
• 330 mg
• 82.5 mg

End-Users

• Hospitals

• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Pregabalin Market Regional Analysis/Insights

The pregabalin market is analyzed and market size insights and trends are provided by country, drug class, application, dosage forms, end-users and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, South Africa, U.A.E., Israel, Egypt, and rest of Middle East and Africa.

North America is expected to dominate the market due to the presence of major key players and rising healthcare expenditure will further propel the market's growth rate in this region. In addition, an increase in the number of research and development activities will further propel the market's growth rate in this region.

L'Asie-Pacifique devrait connaître une croissance au cours de la période de prévision en raison de la prévalence croissante des convulsions et des troubles anxieux dans cette région. En outre, le développement des infrastructures de santé et l'augmentation de la population gériatrique propulseront davantage le taux de croissance du marché dans cette région.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.   

Croissance des infrastructures de santé Base installée et pénétration des nouvelles technologies

Le marché de la prégabaline vous fournit également une analyse détaillée du marché pour chaque pays, la croissance des dépenses de santé pour les équipements en capital, la base installée de différents types de produits pour le marché de la prégabaline, l'impact de la technologie à l'aide de courbes de vie et les changements dans les scénarios réglementaires des soins de santé et leur impact sur le marché de la prégabaline. Les données sont disponibles pour la période historique 2010-2020.

Analyse du paysage concurrentiel et des parts de marché mondiales de la prégabaline

Le paysage concurrentiel du marché de la prégabaline fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination de l'application. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché de la prégabaline.

Certains des principaux acteurs opérant sur le marché de la prégabaline sont :

• Pfizer Inc. (États-Unis)
• GlaxoSmithKline plc (Royaume-Uni)
• Novartis SA (Suisse)
• Mylan NV (États-Unis)
• Teva Pharmaceutical Industries Ltd. (Israël)
• Sanofi (France)
• F. Hoffmann-La Roche SA (Suisse)
• Aurobindo Pharma (Inde)
• Lupin (Inde)
• Zydus Cadila (Inde)
• Amneal Pharmaceuticals LLC. (États-Unis)
• Cipla Inc. (États-Unis)
• Torrent Pharmaceuticals Ltd. (Inde)
• Glenmark Pharmaceuticals Limited (Inde)
• Medley Pharmaceuticals Ltd. (Inde)
• Genesis Biotec Inc. (Inde)
• Société pharmaceutique Biomax (Royaume-Uni)
• ZCL Chemicals Ltd. (Inde)
• Olon SpA (Italie)
• HIKAL Ltd. (Inde)

SKU-58532